Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc. (ORMP)
Filing Type: Form 8-K (Current Report)
Date of Report: February 7, 2025 (Event Date)
Subject: Entry into a Material Definitive Agreement regarding a Joint Venture (JV) with Hefei Tianhui Biotech Co., Ltd. ("HTIT").
The Company, along with Oramed Ltd. and HTIT, entered into an Ancillary Agreement Completion Protocol and Supplemental Agreement to amend a prior Joint Venture Agreement. This transaction establishes "Oramed NewCo, Inc." as the joint venture entity focused on the funding, development, production, marketing, and distribution of specific products, including oral insulin and an oral semaglutide candidate (HT01B).
Key Financial Metrics and Transaction Terms
This filing details a capital structure and funding plan rather than historical financial performance. Key monetary terms include:
- Initial Closing Funding (Target Date: April 30, 2025):
- HTIT Investment: $40 million to Oramed NewCo.
- Company and Oramed Ltd. Contribution: $7.5 million to Oramed NewCo.
- Non-refundable Deposit to HTIT: $20 million (from Oramed NewCo).
- Second Closing Funding (Target Date: Post-April 30, 2025):
- HTIT Investment: $20 million to Oramed NewCo.
- Company and Oramed Ltd. Contribution: $7.5 million to Oramed NewCo.
- Non-refundable Deposit to HTIT: $10 million (from Oramed NewCo).
- Expense Reimbursements: Oramed NewCo to reimburse the Company/Oramed Ltd. and HTIT $500,000 each for transaction expenses, plus operational expenses for the phase III clinical trial for oral insulin.
- Equity Issuance:
- Initial Closing: HTIT receives 6,153,746 shares + 100 Founder Shares; Company receives 1,153,746 shares + 100 Founder Shares.
- Second Closing: HTIT receives 3,076,923 shares; Company receives 1,153,846 shares.
- Asset Transfer Consideration: Company to receive 6,923,076 shares in two tranches.
Note: The filing text does not provide historical revenue, profit, cash flow, margins, or debt figures for the Company.
Material Changes and Transaction Structure
The Supplemental Agreement introduces significant structural changes to the Company's operations and governance:
- Spin-Off: The Company plans to distribute no less than 60% of Oramed NewCo shares to its shareholders as an in-kind distribution (Spin Off) following the Initial Closing.
- Asset Transfer: The Company and Oramed Ltd. will transfer all rights to Transferred IP, Business Contracts, and Regulatory Information to Oramed NewCo in exchange for equity.
- Licensing and Supply:
- License Agreement: HTIT grants Oramed NewCo an exclusive, royalty-free license for HT01B (oral semaglutide) outside of Greater China.
- Supply Agreement: HTIT will manufacture and supply products to Oramed NewCo for an initial term of five years, renewable for three-year terms.
- Novation: The existing Technology License Agreement (TLA) is novated to become an agreement between HTIT Biotech and Oramed NewCo, releasing prior parties from claims.
Guidance, Outlook, and Risks
Closing Deadlines and Conditions:
- Initial Closing: Deadline is April 30, 2025.
- Second Closing: Must occur no later than the fifth business day after closing conditions are met, but not before April 30, 2025 unless Oramed NewCo stock is listed on Nasdaq. If listing fails by April 30, the deadline extends to May 31, 2025.
- Termination Right: Either party may terminate if the Second Closing does not occur by September 1, 2025.
- HTIT may designate three directors and nominate two of the four independent directors.
- The Company retains the right to nominate the other two independent directors and appoint two directors as long as it holds at least 2,153,846 shares.
- Both the Company and HTIT are restricted from selling or transferring Oramed NewCo equity for 120 days following the Listing Date.
- The filing contains forward-looking statements regarding the Spin Off and related transactions, which are subject to risks and uncertainties.
- Success depends on the satisfaction of closing conditions, including governmental approvals and Nasdaq listing.
Investor Verification Checklist
- Verify the status of the Nasdaq listing application for Oramed NewCo, as this dictates the Second Closing timeline.
- Confirm the specific terms of the "Transferred Assets" (IP and contracts) moving to Oramed NewCo via the Asset Transfer Agreement.
- Monitor the $20 million and $10 million non-refundable deposits to HTIT and their impact on Oramed NewCo's liquidity.
- Review the "Spin Off" mechanics to understand the exact percentage of Oramed NewCo shares to be distributed to existing Oramed shareholders.
- Assess the implications of the royalty-free license for HT01B on future revenue projections for the joint venture.